Tumor necrosis factor (TNF) and interferon gamma (IFN-'y) are pleuripotent cytokines and have multiple functions during the inflammatory response. Using a murine model of autoimmune myocarditis, we studied the role of TNF and IFN-y in myocardial inflammation. Neutralizing monoclonal antibodies against TNF-cx/f and IFN-ywere administered to myosin-immunized A/J mice to assess the effect on the severity of myocardial inflammation. Anti-TNF treatment significantly reduced the severity of myocarditis compared with rat immunoglobulin G or saline controls (p<0.0007) when given before myosin immunization. Myosin-specific lymph node T-cell proliferation studies showed no difference in the proliferative response between the anti-TNF-treated mice and controls. Administration of anti-TNF to mice after myosin immunization had no effect on the severity of inflammation. This suggests that TNF is an important mediator early in the pathogenesis of myocardial inflammation in this model of myocarditis. Neutralization of IFN-y significantly increased the severity of myocarditis compared with rat immunoglobulin G and saline controls (p<0.0065), suggesting that IFN-y may function as an important regulatory cytokine early in the pathogenesis of myocardial inflammation. Understanding the functions of cytokines during the inflammatory response to myocardial injury may provide important information on possible methods to limit myocardial
I njury to the myocardium can result from a variety of causes, including ischemia, allograft rejection, autoimmune diseases, infection, and anthracycline drugs. Regardless of the cause of injury, an inflammatory response results in order to begin repair and restoration of the injured myocardium. Though inflammation is clearly beneficial in mediating myocardial tissue repair, there can be pathological consequences of the inflammatory response. For example, in models of ischemic injury to the myocardium, both activation of the complement cascade'-4 and enhanced neutrophil transendothelial migration5-8 are involved in augmenting tissue injury induced by ischemia. Weisman et a19 demonstrated that administration of soluble human complement receptor type 1 to rats with experimental myocardial infarction reduced the severity of inflammation and necrosis. Several studies10-12 suggest that blockade of leukocyte adhesion is important in limiting inflammatory injury. Cytokines may also have an important effect on the myocardium. As shown by the studies of Gulick et al,13 both tumor necrosis factor (TNF) and interleukin-1 can inhibit the response of isolated myocytes to ,B-adrenergic stimuli. These findings could have important implications concerning the role of inflammatory cytokines in accentuating impaired myocardial performance during an inflammatory response to cardiac injury. In addition, Lane et al14 recently reported that administration of lipopolysaccharide to Coxsackievirus B3-resistant B1O.A mice rendered them susceptible to Coxsackievirus B3-induced myocarditis. Many cytokines such as interleukin-1, TNF, and interferon gamma (IFN-y) are produced in response to lipopolysaccharide administration, and this study suggests that inflammatory cytokines may play an important role in determining susceptibility to viral myocarditis. It is clear that identification of the pathways by which viable myocardium can be damaged during the inflammatory response to different causes of injury will be important in finding ways to limit additional tissue damage incurred and to preserve cardiac function during the process of tissue repair.
We were interested to learn more about the role of cytokines in the induction and progression of myocardial injury that results specifically from the inflammatory response, distinct from other contributing causes of injury. In a murine model of autoimmune myocarditis, originally described by Neu et 
Lymph Node T-cell Proliferation Studies
One hundred micrograms of cardiac myosin emulsified in CFA was prepared as described above and injected subcutaneously into male A/J mice. The mice also received 500 ng pertussis toxin by intraperitoneal injection at the time of myosin immunization. Seven days after the immunization, the draining lymph nodes were aseptically removed into Hanks' balanced salt solution (GIBCO, Grand Peptide concentration was estimated by the Bradford assay (Bio-Rad Laboratories, Richmond, Calif.).
Induction of Myocarditis
The induction of myocarditis and histological methods have been previously described.16 Briefly, mouse cardiac myosin was isolated and purified, and 100 ,ug purified myosin was emulsified in CFA and injected subcutaneously on day 1 and day 7. Five hundred nanograms of pertussis toxin was injected intraperitoneally on day 1 only. Immunization of A/J mice with myosin/CFA and pertussis toxin reproducibly causes myocarditis in -96% of the mice.16 Though the mice showed no specific signs of congestive heart failure, such as respiratory difficulty, peripheral edema, or ascites, some mice had ruffled fur and appeared weak and ill. On day 21, the mice were killed by cervical dislocation; the hearts were excised and immediately placed into 10% buffered formalin. In many cases, necrosis of the epicardium was visibly apparent on excision. The tissue was embedded in paraffin, and serial 8-10-,um step sections were made through the entire heart and stained with hematoxylin and eosin. Myocarditis was defined as the presence of a lymphocytic infiltrate and adjacent myocardial necrosis. 17 The lesions were composed of an provide adequate neutralization of endogenously pro-interstitial infiltrate predominantly consisting of macrophages, neutrophils, and T cells. The surrounding myocytes appeared to be injured and in various stages of cell death with vacuolated cytoplasms, fragmented cell membranes, and pyknotic nuclei. The severity of myocarditis was determined by estimating the percentage of inflamed myocardium in the most severely affected cross section after all sections throughout each heart were reviewed according to a previously published grading scale.16 This grading scale was developed such that by visual inspection of the sections under low power ( x 20), we could view the entire cross section and reproducibly separate hearts with >50%, 10-50%, <10%, or no inflammation. Because no assumptions about the normal distribution of myocarditis severity in a population of A/J mice were made with these methods, we could then use a nonparametric analysis to test if significant differences were present between the treatment groups. Each heart was assigned points in order to compare the severity of myocarditis between different treatment groups according to the following scale: normal, no inflammation (one point); minimal, 0-10% inflammation (two points); moderate, 10-50% inflammation (three points); severe, >50% inflammation (four points). All estimations were made under low power by one reviewer (S.C.S.) who was blinded to the identity of the slide. Representative examples of the histological findings in these studies are found in Figure 1 .
Statistics
Differences in the severity of myocarditis between the treatment groups were assessed by the MannWhitney rank-sum test22 using the STATVIEW II program (Abacus Concepts, Inc., Berkeley, Calif.) on a Macintosh lIcx computer.
Results

Neutralization of TNF Ameliorates the Severity of Myocarditis
The effect of TNF neutralization on the severity of myocarditis was studied by initiating anti-TNF mAb treatment before myosin/CFA immunization. A neutralizing dose (250 ,g) of the anti-TNF a1f3 mAb TN3-19.1220 was given on days 0, 6, 13, and 20, and the mice were immunized with myosin/CFA on days 1 and 7. The results of these studies are shown in Table 1 , and photomicrographs of the histological findings are shown in Figure 1 . Of the 35 A/J mice treated with TN3-19.12, eight were normal, 17 had minimal myocardial inflammation, five had moderate myocardial inflammation, and five had severe inflammation. In contrast, none of the 20 mice treated with control rat IgG had normal hearts: six had minimal inflammation, four had moderate inflammation, and 10 had severe inflammation.
There was no significant difference in the severity of myocarditis between the rat IgG and saline control groups (p<0.7). The reduction in the severity of myocardial inflammation found in the TN3-19.12-treated group compared with the rat IgG control group was statistically significant at p<0.0007. Thus, treatment with anti-TNF mAb dramatically reduced the severity of myocarditis. These results suggest that TNF is an important mediator of myocardial inflammation in this inflammatory process and that IFN-y has unexpected anti-inflammatory functions in this model of cardiacspecific inflammation.
These data clearly show that neutralization of endogenous TNF ameliorates the severity of myosin-induced autoimmune myocarditis. Because TN3-19.12 recognizes TNF-a and TNF-f8, the decrease in severity of myocarditis seen could be due to neutralization of either or both of these cytokines. When TN3-19.12 was administered before immunization with myosin/CFA, the severity of myocardial inflammation was significantly reduced. In addition, anti-TNF treatment did not block the activation or proliferation of cardiac myosinreactive T cells. Possible key effects of TNF on the process of myocardial inflammation include its role in major histocompatibility complex class I and class II gene expression and intercellular adhesion molecule expression. Because TNF is secreted by activated macrophages and can act synergistically with IFN-y to increase the expression of both major histocompatibility complex chain class J24-27 and class 1128-32 molecules, interference with these events could have important effects on the processing and presentation of cardiac myosin peptides to T cells. The lymph node proliferation studies showed that the T-cell response to cardiac myosin was preserved, regardless of whether the mice received neutralizing doses of anti-TNF or anti-IFN-y mAb. This suggests that, at least in the regional lymph nodes of these mice, processing and presentation of cardiac myosin peptides was sufficient to activate T Values are the numbers of mice evaluated after death by cervical dislocation at each day of study according to the histological severity of myocarditis as described in "Materials and Methods." Immunizations of myosin emulsified in complete Freund's adjuvant were given on days 1 and 7, as per the usual treatment protocol. Values are the numbers of mice in each treatment group according to the severity of myocarditis as determined by histological analysis and described in "Materials and Methods." IgG, immunoglobulin G; TNF, tumor necrosis factor; NS, not significant. Severity of myocarditis is ranked as follows: normal, 1; minimal, 2; moderate 3, severe, 4. Immunizations of myosin emulsified in complete Freund's adjuvant were given on days 1 and 7, according to the usual treatment protocol. TN3-19.12 or control hamster IgG were given by intraperitoneal injection on the days shown. The results are pooled from two separate experiments. Differences in the severity of myocarditis between the groups were determined by the Mann-Whitney rank-sum test. 22 cells, but this assay does not test whether these activated T cells reach the myocardium and remain activated. With regard to cellular trafficking, it is well established that TNF-a is important in recruiting immune effector cells to sites of inflammation by increasing the expression of intercellular adhesion molecule-i (ICAM-1) and endothelial leukocyte adhesion molecule-1 on endothelial cells33,34 and thereby enhancing the ability of cells expressing leukocyte function-related antigen-1 to bind to the endothelia and migrate into sites of tissue inflammation.56 We favor the hypothesis that neutralization of TNF could directly impair the ability of T cells, monocytes, and neutrophils to migrate from the circulation into the myocardium and thus prevent 
